Skip to main content

Table 3 Appropriateness of empiric therapy

From: Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

  Ceftolozane/tazobactam Piperacillin/tazobactam
Resistant to initial therapy (%) 7.8 20.2
Susceptible to initial therapy (%) 92.2 79.8